Trial Profile
Bioequivalence study comparing fixed dose combination of Daclatasvir/Sofosbuvir with individual reference product.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics; Therapeutic Use
- 17 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.